Name | Number of supported studies | Average coverage | |
---|---|---|---|
ciliated cell | 3 studies | 22% ± 8% | |
epithelial cell | 3 studies | 31% ± 10% | |
GABAergic neuron | 3 studies | 23% ± 3% | |
astrocyte | 3 studies | 20% ± 4% | |
glutamatergic neuron | 3 studies | 25% ± 2% |
Name | Number of supported studies | Average coverage | |
---|---|---|---|
brain | 3 studies | 22% ± 3% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
prostate | 100% | 2099.79 | 245 / 245 | 100% | 6.61 | 502 / 502 |
esophagus | 100% | 1621.61 | 1443 / 1445 | 100% | 6.67 | 183 / 183 |
intestine | 100% | 2000.78 | 966 / 966 | 100% | 5.55 | 525 / 527 |
bladder | 100% | 2017.67 | 21 / 21 | 99% | 5.14 | 501 / 504 |
thymus | 100% | 3640.40 | 653 / 653 | 99% | 5.50 | 601 / 605 |
breast | 100% | 2281.70 | 459 / 459 | 99% | 6.47 | 1107 / 1118 |
kidney | 100% | 1507.72 | 89 / 89 | 99% | 5.52 | 891 / 901 |
pancreas | 99% | 1586.89 | 326 / 328 | 99% | 5.90 | 177 / 178 |
stomach | 100% | 1908.79 | 358 / 359 | 99% | 5.27 | 283 / 286 |
skin | 100% | 1995.25 | 1805 / 1809 | 99% | 5.21 | 466 / 472 |
lung | 100% | 3054.47 | 578 / 578 | 98% | 5.93 | 1136 / 1155 |
adrenal gland | 100% | 1802.57 | 258 / 258 | 98% | 3.87 | 226 / 230 |
uterus | 100% | 2278.81 | 170 / 170 | 98% | 4.02 | 449 / 459 |
ovary | 100% | 2244.13 | 180 / 180 | 93% | 3.80 | 400 / 430 |
liver | 97% | 975.17 | 220 / 226 | 92% | 2.91 | 372 / 406 |
brain | 78% | 611.64 | 2055 / 2642 | 100% | 6.06 | 702 / 705 |
spleen | 100% | 2933.22 | 241 / 241 | 0% | 0 | 0 / 0 |
ureter | 0% | 0 | 0 / 0 | 100% | 3.37 | 1 / 1 |
adipose | 100% | 1922.20 | 1203 / 1204 | 0% | 0 | 0 / 0 |
blood vessel | 99% | 1375.77 | 1326 / 1335 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 98% | 3.87 | 44 / 45 |
lymph node | 0% | 0 | 0 / 0 | 97% | 3.55 | 28 / 29 |
eye | 0% | 0 | 0 / 0 | 95% | 3.86 | 76 / 80 |
heart | 90% | 758.83 | 779 / 861 | 0% | 0 | 0 / 0 |
peripheral blood | 88% | 1237.40 | 815 / 929 | 0% | 0 | 0 / 0 |
muscle | 81% | 549.93 | 652 / 803 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_0016567 | Biological process | protein ubiquitination |
GO_0009411 | Biological process | response to UV |
GO_0006283 | Biological process | transcription-coupled nucleotide-excision repair |
GO_0005694 | Cellular component | chromosome |
GO_0005654 | Cellular component | nucleoplasm |
GO_0000993 | Molecular function | RNA polymerase II complex binding |
GO_0005515 | Molecular function | protein binding |
Gene name | UVSSA |
Protein name | UV stimulated scaffold protein A UV-stimulated scaffold protein A |
Synonyms | KIAA1530 |
Description | FUNCTION: Factor involved in transcription-coupled nucleotide excision repair (TC-NER), a mechanism that rapidly removes RNA polymerase II-blocking lesions from the transcribed strand of active genes . Facilitates the ubiquitination of the elongating form of RNA polymerase II (RNA pol IIo) at DNA damage sites, thereby promoting RNA pol IIo backtracking and access by the TC-NER machinery to lesion sites . Acts by promoting stabilization of ERCC6 by recruiting deubiquitinating enzyme USP7 to TC-NER complexes, preventing UV-induced degradation of ERCC6 by the proteasome . Also facilitates transfer of TFIIH to RNA polymerase II . Not involved in processing oxidative damage . . |
Accessions | ENST00000389851.10 [Q2YD98-1] Q2YD98 ENST00000512728.5 [Q2YD98-2] A0A7I2V3L2 H0Y924 ENST00000507531.5 [Q2YD98-1] ENST00000677428.1 A0A7I2V4K1 A0A7I2V554 ENST00000511216.6 [Q2YD98-1] ENST00000679192.1 [Q2YD98-1] ENST00000679242.1 ENST00000677286.1 [Q2YD98-1] ENST00000678994.1 ENST00000503548.1 |